Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie and Calico will each contribute another $500 million to extend their long-running aging research collaboration, the companies said Tuesday. The…
AbbVie and Calico Life Sciences said on Tuesday they would extend their seven-year-old research collaboration with each company contributing an additional…
The second extension of the Calico-AbbVie aging research collaboration brings cumulative committed capital to roughly $2.5 billion, making it one of the…
Source summaries from our enrichment pipeline; follow links for originals.
All 13 sources with sentiment breakdown →
AbbVie and Calico Life Sciences announced the second extension of their 2014 aging and age-related disease collaboration on July 27, 2021, with each partner committing an additional ~$500M (~$1B incremental; ~$3.5B cumulative alliance value). The pipeline spanned 20+ early-stage programs in immuno-oncology and neurodegeneration, with three in clinical development at the time, anchored by the PTPN2/N1 inhibitor osunprotafib (ABBV-CLS-484) in oncology and the eIF2B activator fosigotifator (ABBV-CLS-7262) in neurodegeneration. OUTCOME: The collaboration ended in November 2025 (reported Nov 12-13). AbbVie wound down the 11-year alliance and laid off ~100 chemists after fosigotifator failed to significantly slow disease progression in the HEALEY ALS Platform Trial (reported Jan 2025) and AbbVie pivoted away from small-molecule discovery toward biologics and genetic medicines. Over its life the alliance produced limited clinical success; the anti-PAPP-A antibody ABBV-CLS-628 (ADPKD; FDA fast-track Oct 2025) and the osunprotafib oncology Phase 1 (NCT04777994) continued under AbbVie at the time of the wind-down.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Calico Life Sciences LLC (this deal) | 2021 | $1.0B | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2021 deals · AbbVie Inc. deals · Neurology deals